Gohibic (Vilobelimab)

Gohibic (vilobelimab) is being evaluated for therapeutic use in conditions where complement-mediated inflammation contributes to disease pathology. The drug is administered intravenously under controlled clinical settings and may be considered when conventional anti‑inflammatory therapies are insufficient.

• Severe sepsis and septic shock where excessive complement activation is implicated.
• Acute respiratory distress syndrome (ARDS) associated with systemic inflammation.
• Certain autoimmune or inflammatory disorders under clinical investigation.
• Potential adjunctive therapy in severe viral infections with hyperinflammatory response.
• Complement C5a‑driven inflammatory complications in organ transplantation.
• Severe inflammatory flare‑ups in rare complement‑mediated diseases.

Adverse events reported with Gohibic are consistent with its mechanism as a complement C5a inhibitor and with the class effects of intravenous monoclonal antibodies. Reactions may occur during or shortly after infusion and can vary in severity.

Common

• Infusion‑related reactions (e.g., flushing, chills, or mild rash).
• Headache, fatigue, or dizziness.
• Nausea, vomiting, or mild gastrointestinal discomfort.
• Transient low‑grade fever or chills.

Serious

• Anaphylaxis or severe hypersensitivity requiring medical intervention.
• Cytokine release syndrome presenting with hypotension, respiratory distress, or organ dysfunction.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.
• Serious infections or sepsis potentially related to immune modulation.

When prescribing Gohibic, clinicians should consider several precautionary measures to minimize risk and ensure appropriate patient monitoring.

• Assess for known hypersensitivity to vilobelimab or any component of the formulation.
• Monitor vital signs and infusion reactions during and after administration.
• Evaluate baseline infection status; avoid use in active uncontrolled infections.
• Use caution in patients with a history of thromboembolic disease.
• Consider renal or hepatic impairment when determining infusion rate.
• Pregnant or breastfeeding status should be reviewed, as safety data are limited.
• Ensure appropriate vaccination status before initiating therapy.

Gohibic may interact with other agents that affect the immune system or hemostasis, and certain concomitant medications should be avoided or used with caution.

Avoid

• Concurrent use of other complement inhibitors or C5a‑targeting biologics.
• Live vaccines administered during treatment.

Use with caution

• Anticoagulants or antiplatelet agents due to potential increased bleeding risk.
• Immunosuppressive drugs that may compound infection risk.
• Cytokine‑modulating therapies that could exacerbate cytokine release syndrome.